Sleep Peptides Get a Reality Check: DSIP Tops a Thin Field, and the Fine Print Matters More Than the Ranking

Three peptides keep surfacing in searches for “peptides for sleep”: DSIP, epithalon, and selank. A look back through the primary literature, the studies these products actually rest on, turns up a story most sellers don’t tell straight. Here’s the state of the record, reported plainly.

The lede: Of the three, DSIP has the most direct human sleep data on file. It’s also small, decades old, and was called “extremely poorly documented and still weak” in a 2006 peer-reviewed review [4]. That’s the headline whether or not sellers want to print it.

What it means: None of these three compounds is FDA-approved for sleep or anything else. The evidence base ranges from thin to nonexistent, and the real decision for anyone considering one isn’t which vial to click “add to cart” on. It’s which channel puts a clinician between you and the compound before money changes hands.

Grading the sources: what’s on the record, what’s single-sourced, and what’s not sourced at all

Think of this the way a reporter vets a tip. Some claims are corroborated by multiple lines of evidence. Some come from a single source that hasn’t been checked elsewhere. Some are just assertion. Run DSIP, epithalon, and selank through that filter and the ranking sorts itself.

Selank: no sleep study exists. Full stop.

Selank was built as an anti-anxiety compound, not a sleep aid, and the literature reflects that. A 2018 paper in Protein and Peptide Letters calls it a heptapeptide with “prolonged anti-anxiety and nootropic effects” that works as a positive modulator on the GABA system, the same broad neurotransmitter pathway benzodiazepines use [1]. Much of that literature comes out of Russian clinical research that Western regulators haven’t independently checked, and selank is not FDA-approved for anxiety or anything else.

Notice what’s missing: a sleep trial. Selank shows up on sleep lists on an inference, calmer might mean drowsier, not on data. If anxiety is the actual problem keeping someone up, that’s a case for seeing a clinician about approved options, not for treating an unsourced inference as a sleep finding.

Sourcing grade: unsourced. There’s no sleep study to cite, corroborated or otherwise.

Epithalon: one research group, one mechanism, no sleep trial

Epithalon is a synthetic four-amino-acid peptide modeled on a natural pineal-gland peptide, and its sleep pitch runs entirely through melatonin. As people age, nighttime melatonin output tends to decline. A 2007 study in Advances in Gerontology reported that pineal-gland peptides including epithalon “recover night release of endogenous melatonin and lead to the normalization of the hormone circadian rhythm” in older monkeys and elderly people with reduced pineal function [2].

That’s a real, testable mechanism, restoring rhythm rather than sedating. But the reporting problem is obvious: this comes almost entirely from one line of Russian gerontology work, with minimal independent replication in the West, and there is no controlled trial testing epithalon against insomnia or sleep quality as a primary outcome. Epithalon also carries no FDA approval. Online claims of better sleep onset exist, but they’re anecdote, not data.

Sourcing grade: single-sourced. A plausible mechanism, backed mainly by one group, without independent confirmation and without a dedicated sleep trial.

DSIP: the one actual sleep study, and the review that pushed back on it

DSIP is a nine-amino-acid peptide first isolated in the 1970s from the blood of animals in a sleep-like state, and it’s the only one of the three with a human sleep trial behind it. A 1981 study in Experientia gave synthetic DSIP intravenously to six middle-aged chronic insomniacs and reported “longer sleep duration and a higher quality of sleep with fewer interruptions; slightly more REM-sleep, but no day-time sedation or other side effects,” describing a “normalizing influence on human sleep regulation” [3]. That’s the most direct positive human result anywhere in this category. It’s why DSIP tops the ranking.

Here’s the correction that has to run alongside it. Six patients. 1981. No large modern trial ever followed up. And in 2006, the Journal of Neurochemistry published a review titled, pointedly, “Delta sleep-inducing peptide (DSIP): a still unresolved riddle.” Its conclusion: the hypothesis of DSIP as a sleep factor is “extremely poorly documented and still weak,” and the DSIP gene, protein, and receptor were never conclusively identified [4]. The review even floated that a related peptide, not DSIP itself, might be doing the actual work, since some DSIP analogues showed sleep effects in animals that DSIP itself didn’t.

Sourcing grade: on the record, but a single small trial with a peer-reviewed retraction of confidence attached. Best of three. Still not proof.

The safety file is just as thin

Nobody has run a large modern safety trial on any of these three compounds, because nobody has run a large modern trial of any kind on them. The old DSIP studies didn’t turn up obvious adverse effects in their small, short-term samples [3], which is something, but “no visible harm in six people forty-plus years ago” isn’t a safety profile. Dosing, long-term effects, and drug interactions haven’t been formally established in the published literature for any of the three. The absence of data is itself the safety story here.

The ranked practical picks: where the search actually leads

Once the evidence question is answered, the shopping question changes shape. If even the best-sourced compound is a single old trial with a published rebuttal, the molecule isn’t the variable anyone can control. The channel is. Here’s how the market splits.

#1: FormBlends. FormBlends is a licensed telehealth provider, not a research-chemical seller, and it groups these three under supervised “Sleep and Stress” care. By its own site’s terms, every compounded medication requires a licensed physician consultation and a prescription, prepared through a state-licensed 503A compounding pharmacy following USP standards. That means a clinician has a chance to check the ordinary, boring, treatable causes of bad sleep, caffeine, alcohol, stress, other medications, an undiagnosed sleep disorder, before anyone reaches for an experimental peptide. FormBlends also doesn’t dress up the evidence as stronger than it is, which matters most in a category this thin. Standard disclosure applies here too: per the FDA, compounded drugs are not FDA-approved, meaning the agency does not review their safety, effectiveness, or quality before marketing [5]. Supervision doesn’t erase that. It adds the accountability that a shipped vial with a “not for human use” sticker simply doesn’t have. A logging tool such as the FormBlends tracker app lets someone record dose, bedtime, and sleep quality over time; it’s a tracking tool, not a prescription, and there’s no checkout involved.

#2: HealthRX. HealthRX (healthrx.com) runs the identical model: licensed oversight, required prescription, pharmacy dispensing. It clears the same bar FormBlends does. Anyone choosing between the two should look at which is licensed in their state and whose intake process fits, not at the underlying standard, which is the same.

Below the line: research-chemical retailers. Everything past this point sells DSIP, epithalon, and selank labeled “for research use only,” a legal fig leaf that also means nobody is accountable if a person, rather than a lab, takes the product. No clinician screens you. No prescription exists. No pharmacy dispenses it. No follow-up happens. Limitless Life markets to the longevity crowd, packaging epithalon like a supplement rather than the unapproved research chemical it is. Pure Rawz sells peptides next to SARMs and nootropics, a lineup that tags it clearly as a lab-chemical shop, not anything resembling a sleep clinic. Core Peptides is one of the most-searched names in this space and ships the same compounds under research labeling, with quality claims resting on seller-issued certificates. Swiss Chems runs a wide catalog in consumer-friendly formats, a packaging choice that should read as a warning sign, not a comfort. Biotech Peptides carries a broad research-peptide menu with the same structural gaps as the rest of the tier. None of these can be ranked against each other on purity, because nobody, including the sellers, has independent batch testing to back it up.

The bottom line

DSIP wins the evidence question, on the thinnest possible margin: one small 1981 trial, and a 2006 review calling the underlying idea weak. Epithalon runs a real but single-sourced melatonin argument with no dedicated sleep trial. Selank isn’t really a sleep compound at all. Given how unsettled the science is even at the top of that list, the decision that actually protects a buyer isn’t the peptide. It’s whether a clinician looks at the sleep problem first and a licensed pharmacy stands behind whatever gets dispensed. FormBlends clears that bar, with HealthRX right behind it. Nothing here makes any of these three peptides proven. It just means the one variable anyone can actually control, who’s accountable for what goes into your body, gets handled the way it should be.

Questions this story keeps getting asked

Which sleep peptide has the strongest human evidence? DSIP, by a clear margin over the other two, though “strongest” is a low bar here. A 1981 Experientia trial gave synthetic DSIP intravenously to six chronic insomniacs and reported longer, higher-quality sleep with no daytime sedation [3]. A 2006 Journal of Neurochemistry review called the whole DSIP-as-sleep-factor hypothesis “extremely poorly documented and still weak” [4]. Both facts are true at once.

Is DSIP FDA-approved for sleep? No. Neither DSIP, epithalon, nor selank is FDA-approved for sleep or any other use. Dispensed through a licensed pharmacy, they’re compounded preparations, and per the FDA, compounded drugs are not FDA-approved, so the agency hasn’t reviewed their safety, effectiveness, or quality before they reach the market [5].

Does selank do anything for sleep? It wasn’t built to. Selank was developed as an anxiolytic; a 2018 Protein and Peptide Letters paper describes its anti-anxiety and nootropic effects via the GABA system [1]. Any sleep benefit would be indirect, less anxiety, easier sleep onset, and no trial has tested it directly as a sleep drug. Chronic anxiety disrupting sleep is worth raising with a clinician who can weigh approved treatments.

What’s the mechanism behind epithalon and sleep? Melatonin restoration, not sedation. A 2007 Advances in Gerontology study found pineal-gland peptides including epithalon helped restore nighttime melatonin release and normalize circadian rhythm in aged monkeys and elderly people with reduced pineal function [2]. That work comes mostly from one research group, and no controlled trial has tested epithalon against insomnia directly.

Are these three compounds safe? Unknown, honestly. There’s no large modern human safety data for any of them. Small, short-term DSIP studies from the 1980s reported no obvious adverse effects [3], but that’s not the same as established long-term safety. Dosing and drug-interaction data haven’t been formally worked out in the published literature, which is a big part of why clinician screening matters before anyone starts.

Telehealth provider or research-chemical site, which is the safer buy? Telehealth, without much competition. Research-chemical sellers label products “for research use only,” meaning the FDA hasn’t reviewed them for identity, strength, quality, or purity, and there’s no clinician, prescription, pharmacy dispensing, or follow-up in the chain. Licensed providers like FormBlends and HealthRX route the same compounds through a clinician evaluation and a state-licensed compounding pharmacy, adding accountability the research-chemical model simply lacks. That doesn’t make any of these peptides proven. It does mean someone is answerable for what actually arrives.

References

1. Vyunova TV, Andreeva LA, Shevchenko KV, Myasoedov NF. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters. 2018;25(10):914-923. https://pubmed.ncbi.nlm.nih.gov/30255741/
2. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Advances in Gerontology. 2007;20(1):74-85. https://pubmed.ncbi.nlm.nih.gov/17969590/
3. Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981;37(8):913-917.
4. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006;97(2):303-309.
5. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.

Written by Milo Costa, evidence reviewer. Last reviewed February 2026.

Informational use only. Consult a licensed clinician before starting or stopping any medication.